Roivant Sciences Ltd. (NASDAQ:ROIV) Director Buys $336,900,200.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Sciences Ltd. Roivant purchased 16,845,010 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the transaction, the director now directly owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This represents a 21.11 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Roivant Sciences Stock Up 2.4 %

Shares of ROIV opened at $11.15 on Friday. The stock has a fifty day simple moving average of $11.79 and a two-hundred day simple moving average of $11.58. The company has a market capitalization of $8.12 billion, a PE ratio of 1.97 and a beta of 1.27. Roivant Sciences Ltd. has a 52-week low of $9.69 and a 52-week high of $13.06.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus target price of $17.93.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors have recently bought and sold shares of the company. TOMS Capital Investment Management LP purchased a new stake in shares of Roivant Sciences during the 3rd quarter valued at approximately $46,333,000. Rubric Capital Management LP lifted its stake in shares of Roivant Sciences by 15.0% in the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after purchasing an additional 3,000,000 shares during the last quarter. Troluce Capital Advisors LLC purchased a new position in shares of Roivant Sciences during the 2nd quarter worth $31,182,000. FMR LLC increased its position in shares of Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after purchasing an additional 2,593,910 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Roivant Sciences by 23.2% during the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock worth $89,400,000 after purchasing an additional 1,460,205 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.